captopril has been researched along with Diabetic Retinopathy in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 9 (39.13) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, K; Gao, X; Hu, C; Jiang, Z; Liu, K | 1 |
| Arnold, AC; Barber, AJ; Dennis, MD; Dierschke, SK; Toro, AL | 1 |
| Baradaran, HR; Khamseh, ME; Safarnejad, B | 1 |
| Jin, HY; Wang, N; Xu, X; Zheng, Z | 1 |
| Eguchi, K; Kario, K; Shimada, K | 1 |
| Efimova, EV; Fedorova, NA; Karpov, RS; Koshel'skaia, OA; Lusta, IV; Vrublevskiĭ, AV | 1 |
| Gao, L; Kern, TS; Widness, M; Xi, X; Zhang, JZ | 1 |
| Aldington, SJ; Holman, RR; Kohner, EM; Matthews, DR; Stratton, IM | 1 |
| Xie, XW; Zhao, P | 1 |
| Fisher, ND; Freeman, KD; Hollenberg, NK; Lansang, CM; Stevanovic, RD | 1 |
| Gao, L; Kern, TS; Xi, X; Zhang, JZ | 1 |
| Chase, HP; Garg, SK; Harris, S; Holmes, DL; Hoops, S; Jackson, WE | 1 |
| Abad, E; Johnston, S; Lucas, A; Reverter, JL; Romero, R; Salinas, I; Sanmarti, A | 1 |
| Bensaoula, T; Ottlecz, A | 2 |
| Asano, T; Fujishima, M; Iwase, M; Nakamura, S; Shi, Ah; Sonoki, K; Takata, Y; Wakisaka, M; Yoshinari, M | 1 |
| Aiello, LP; Clermont, A; Feener, EP; Hata, Y; Pokras, F; Rook, SL; Suzuma, I; Suzuma, K | 1 |
| Chase, HP; Garg, SK; Harris, S; Holmes, DL; Jackson, WE | 1 |
| Engler, CB; Larsen, M; Lund-Andersen, H; Mathiesen, ER; Parving, HH | 1 |
| Hommel, E; Larsen, M; Lund-Andersen, H; Parving, HH | 2 |
1 review(s) available for captopril and Diabetic Retinopathy
| Article | Year |
|---|---|
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Captopril; Cardiomegaly; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetic Retinopathy; Humans; Hypertension; Irbesartan; Kidney Diseases; Losartan; Practice Guidelines as Topic; Risk; Tetrazoles | 2002 |
8 trial(s) available for captopril and Diabetic Retinopathy
| Article | Year |
|---|---|
Treatment effects of captopril on non-proliferative diabetic retinopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Captopril; Diabetic Retinopathy; Female; Humans; Male; Middle Aged; Treatment Outcome; Young Adult | 2012 |
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Blood Pressure; Captopril; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Female; Humans; Hypertension, Renal; Laser Coagulation; Male; Middle Aged; Prospective Studies; Risk Factors; Vision Disorders; Vitreous Hemorrhage | 2004 |
Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial.
Topics: Adolescent; Adult; Albuminuria; Blood Pressure; Captopril; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Male; Placebos; Prognosis | 1993 |
Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors.
Topics: Albuminuria; Blood Glucose; Blood Pressure; Captopril; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Diastole; Female; Follow-Up Studies; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Male; Middle Aged; Renal Circulation; Systole; Triglycerides | 1993 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Glucose; Captopril; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Female; Follow-Up Studies; Humans; Hypertension; Hypoglycemia; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Peripheral Vascular Diseases; Prospective Studies; Proteinuria; Visual Acuity; Weight Gain | 1998 |
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Captopril; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemia; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Peripheral Vascular Diseases; Prospective Studies; Treatment Outcome; Visual Acuity; Weight Gain | 1998 |
Blood-retina barrier permeability in diabetes during acute ACE-inhibition.
Topics: Adult; Albuminuria; Blood-Retinal Barrier; Captopril; Cell Membrane Permeability; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Double-Blind Method; Female; Fluorescein; Fluorescein Angiography; Fluoresceins; Fluorophotometry; Humans; Hypertension; Male; Middle Aged | 1991 |
Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy.
Topics: Adult; Blood Glucose; Blood Pressure; Blood-Retinal Barrier; Captopril; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Retinopathy; Female; Fluorescein; Fluoresceins; Hemoglobin C; Humans; Male; Permeability; Prospective Studies | 1990 |
14 other study(ies) available for captopril and Diabetic Retinopathy
| Article | Year |
|---|---|
Captopril alleviates oxidative damage in diabetic retinopathy.
Topics: Animals; Captopril; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Endothelial Cells; Glucose; Humans; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Retina; Retinal Vessels; Streptozocin; Tyrosine; Vascular Endothelial Growth Factor A | 2022 |
Angiotensin-(1-7) Attenuates Protein O-GlcNAcylation in the Retina by EPAC/Rap1-Dependent Inhibition of O-GlcNAc Transferase.
Topics: Angiotensin I; Animals; Captopril; Cyclic AMP-Dependent Protein Kinases; Diabetic Retinopathy; Mice; N-Acetylglucosaminyltransferases; Peptide Fragments; Renin-Angiotensin System; Retina; Signal Transduction | 2020 |
The effect of captopril on progression of retinopathy in type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Body Mass Index; Captopril; Case-Control Studies; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Regression Analysis | 2009 |
[Effect of long term therapy with captopril on dopplerographic parameters of intrarenal blood flow and renal function in patients with hypertension and diabetes].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Captopril; Diabetes Complications; Diabetic Retinopathy; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Renal Artery; Time; Ultrasonography, Doppler | 2002 |
Captopril inhibits glucose accumulation in retinal cells in diabetes.
Topics: Adrenergic beta-Antagonists; Aldehyde Reductase; Angiotensin-Converting Enzyme Inhibitors; Animals; Atenolol; Blood Glucose; Blotting, Western; Captopril; Cattle; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelium, Vascular; Glucose; Glucose Transporter Type 1; Lisinopril; Male; Monosaccharide Transport Proteins; Rats; Rats, Sprague-Dawley; Retina; Retinal Vessels | 2003 |
[The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Mice; Random Allocation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2004 |
Short- and long-term glycaemic control and the state of the renin system in type 1 diabetes mellitus.
Topics: Antihypertensive Agents; Blood Glucose; Captopril; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Diabetic Retinopathy; Gastroparesis; Homeostasis; Humans; Hyperlipidemias; Hypertension; Renin; Sodium, Dietary; Thyroid Diseases | 2007 |
Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Body Weight; Capillaries; Captopril; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cells; Hyperglycemia; Leukostasis; Losartan; Male; Rats; Rats, Inbred Lew; Retina; Retinal Vessels; Vascular Cell Adhesion Molecule-1 | 2007 |
Captopril ameliorates the decreased Na+,K(+)-ATPase activity in the retina of streptozotocin-induced diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Bacterial Agents; Blood Glucose; Captopril; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Enzyme Inhibitors; Isoenzymes; Male; Ouabain; Peptidyl-Dipeptidase A; Random Allocation; Rats; Retina; Sodium-Potassium-Exchanging ATPase; Streptozocin | 1996 |
Suppression of sodium-dependent glucose uptake by captopril improves high-glucose-induced morphological and functional changes of cultured bovine retinal pericytes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biological Transport, Active; Captopril; Cattle; Cell Size; Cells, Cultured; Diabetic Retinopathy; Glucose; Humans; Inositol; Pericytes; Retina; Sodium; Thymidine | 1999 |
Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Captopril; Cattle; Cells, Cultured; Diabetic Angiopathies; Diabetic Retinopathy; Endothelium, Vascular; Hypertension; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Retinal Vessels; RNA, Messenger; Stress, Mechanical; Tetrazoles | 2001 |
Biochemical and ultrastructural studies in the neural retina and retinal pigment epithelium of STZ-diabetic rats: effect of captopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Peptidyl-Dipeptidase A; Pigment Epithelium of Eye; Rats; Rats, Long-Evans; Retina; Sodium-Potassium-Exchanging ATPase | 2001 |
Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy.
Topics: Adolescent; Adult; Captopril; Creatinine; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Female; Glycated Hemoglobin; Humans; Male; Pilot Projects | 1992 |
Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 (insulin-dependent) diabetic patients with background retinopathy.
Topics: Adult; Albuminuria; Bendroflumethiazide; Blood Glucose; Blood Pressure; Blood-Retinal Barrier; Captopril; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Retinopathy; Female; Fluorescein; Fluoresceins; Furosemide; Glomerular Filtration Rate; Humans; Male; Middle Aged | 1989 |